5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Buy
51
LENZ Quote, Financials, Valuation and Earnings
Last price:
$25.91
Seasonality move
:
1.12%
Day range:
$25.15 - $26.77
52-week range:
$14.42 - $38.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.42x
Volume:
182.1K
Avg. volume:
286.2K
1-year change:
54.23%
Market cap:
$697.9M
Revenue:
--
EPS (TTM):
-$4.77
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | -$0.32 | -- | -82.44% | $44.63 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
IFRX
InflaRx NV
|
$36.3K | -$0.20 | -5.26% | -0.05% | $9.56 |
|
MAZE
Maze Therapeutics
|
-- | -$0.63 | -- | -- | $25.67 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.48 | -- | -35.68% | $39.14 |
|
PETS
PetMed Express
|
$54M | -- | -18.8% | -- | $3.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
$25.34 | $44.63 | $697.9M | -- | $1.03 | 0% | -- |
|
CDT
Conduit Pharmaceuticals
|
$0.42 | -- | $4M | -- | $0.00 | 0% | -- |
|
IFRX
InflaRx NV
|
$1.49 | $9.56 | $100M | -- | $0.00 | 0% | 483.13x |
|
MAZE
Maze Therapeutics
|
$9.49 | $25.67 | $406.4M | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$9.54 | $39.14 | $357.2M | -- | $19.36 | 0% | -- |
|
PETS
PetMed Express
|
$3.62 | $3.60 | $74.8M | 362.00x | $0.30 | 0% | 0.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | 0.772 | -- | -- |
|
CDT
Conduit Pharmaceuticals
|
-- | 2.365 | -- | -- |
|
IFRX
InflaRx NV
|
-- | 4.290 | -- | 3.85x |
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -0.428 | -- | -- |
|
PETS
PetMed Express
|
-- | 1.004 | -- | 1.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LENZ
LENZ Therapeutics
|
-- | -$15.2M | -- | -- | -- | -$9.2M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$5.8M | -- | -- | -- | -$2M |
|
IFRX
InflaRx NV
|
-$3M | -$10.4M | -56.78% | -56.78% | 1207051.66% | -$12.3M |
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
PETS
PetMed Express
|
$14.9M | -$450K | 0.37% | 0.37% | -0.85% | -$1.9M |
LENZ Therapeutics vs. Competitors
-
Which has Higher Returns LENZ or CDT?
Conduit Pharmaceuticals has a net margin of -- compared to LENZ Therapeutics's net margin of --. LENZ Therapeutics's return on equity of -- beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.46 -- CDTConduit Pharmaceuticals-- -$0.07 -- -
What do Analysts Say About LENZ or CDT?
LENZ Therapeutics has a consensus price target of $44.63, signalling upside risk potential of 76.11%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that LENZ Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe LENZ Therapeutics is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics5 0 0 CDTConduit Pharmaceuticals0 0 0 -
Is LENZ or CDT More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or CDT?
LENZ Therapeutics has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or CDT?
LENZ Therapeutics quarterly revenues are --, which are smaller than Conduit Pharmaceuticals quarterly revenues of --. LENZ Therapeutics's net income of -$12.7M is lower than Conduit Pharmaceuticals's net income of -$6.5M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$12.7M CDTConduit Pharmaceuticals-- -- -- -$6.5M
-
Which has Higher Returns LENZ or IFRX?
InflaRx NV has a net margin of -- compared to LENZ Therapeutics's net margin of -14092.9%. LENZ Therapeutics's return on equity of -- beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.46 -- IFRXInflaRx NV-5376.61% -$0.09 $63.9M -
What do Analysts Say About LENZ or IFRX?
LENZ Therapeutics has a consensus price target of $44.63, signalling upside risk potential of 76.11%. On the other hand InflaRx NV has an analysts' consensus of $9.56 which suggests that it could grow by 540.12%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, analysts believe InflaRx NV is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics5 0 0 IFRXInflaRx NV5 1 0 -
Is LENZ or IFRX More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.18%.
-
Which is a Better Dividend Stock LENZ or IFRX?
LENZ Therapeutics has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or IFRX?
LENZ Therapeutics quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of -$450. LENZ Therapeutics's net income of -$12.7M is lower than InflaRx NV's net income of -$5.4M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 483.13x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$12.7M IFRXInflaRx NV483.13x -- -$450 -$5.4M
-
Which has Higher Returns LENZ or MAZE?
Maze Therapeutics has a net margin of -- compared to LENZ Therapeutics's net margin of --. LENZ Therapeutics's return on equity of -- beat Maze Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.46 -- MAZEMaze Therapeutics-- -- -- -
What do Analysts Say About LENZ or MAZE?
LENZ Therapeutics has a consensus price target of $44.63, signalling upside risk potential of 76.11%. On the other hand Maze Therapeutics has an analysts' consensus of $25.67 which suggests that it could grow by 170.46%. Given that Maze Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Maze Therapeutics is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics5 0 0 MAZEMaze Therapeutics3 0 0 -
Is LENZ or MAZE More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LENZ or MAZE?
LENZ Therapeutics has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENZ Therapeutics pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or MAZE?
LENZ Therapeutics quarterly revenues are --, which are smaller than Maze Therapeutics quarterly revenues of --. LENZ Therapeutics's net income of -$12.7M is higher than Maze Therapeutics's net income of --. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$12.7M MAZEMaze Therapeutics-- -- -- --
-
Which has Higher Returns LENZ or ORKA?
Oruka Therapeutics has a net margin of -- compared to LENZ Therapeutics's net margin of --. LENZ Therapeutics's return on equity of -- beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.46 -- ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About LENZ or ORKA?
LENZ Therapeutics has a consensus price target of $44.63, signalling upside risk potential of 76.11%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.14 which suggests that it could grow by 310.3%. Given that Oruka Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Oruka Therapeutics is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics5 0 0 ORKAOruka Therapeutics7 0 0 -
Is LENZ or ORKA More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.841%.
-
Which is a Better Dividend Stock LENZ or ORKA?
LENZ Therapeutics has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. LENZ Therapeutics pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or ORKA?
LENZ Therapeutics quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. LENZ Therapeutics's net income of -$12.7M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$12.7M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns LENZ or PETS?
PetMed Express has a net margin of -- compared to LENZ Therapeutics's net margin of -1.33%. LENZ Therapeutics's return on equity of -- beat PetMed Express's return on equity of 0.37%.
Company Gross Margin Earnings Per Share Invested Capital LENZLENZ Therapeutics-- -$0.46 -- PETSPetMed Express28.14% -$0.03 $96.2M -
What do Analysts Say About LENZ or PETS?
LENZ Therapeutics has a consensus price target of $44.63, signalling upside risk potential of 76.11%. On the other hand PetMed Express has an analysts' consensus of $3.60 which suggests that it could fall by -0.55%. Given that LENZ Therapeutics has higher upside potential than PetMed Express, analysts believe LENZ Therapeutics is more attractive than PetMed Express.
Company Buy Ratings Hold Ratings Sell Ratings LENZLENZ Therapeutics5 0 0 PETSPetMed Express0 1 1 -
Is LENZ or PETS More Risky?
LENZ Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PetMed Express has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.336%.
-
Which is a Better Dividend Stock LENZ or PETS?
LENZ Therapeutics has a quarterly dividend of $1.03 per share corresponding to a yield of 0%. PetMed Express offers a yield of 0% to investors and pays a quarterly dividend of $0.30 per share. LENZ Therapeutics pays -- of its earnings as a dividend. PetMed Express pays out -166.63% of its earnings as a dividend.
-
Which has Better Financial Ratios LENZ or PETS?
LENZ Therapeutics quarterly revenues are --, which are smaller than PetMed Express quarterly revenues of $53M. LENZ Therapeutics's net income of -$12.7M is lower than PetMed Express's net income of -$707K. Notably, LENZ Therapeutics's price-to-earnings ratio is -- while PetMed Express's PE ratio is 362.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENZ Therapeutics is -- versus 0.30x for PetMed Express. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LENZLENZ Therapeutics-- -- -- -$12.7M PETSPetMed Express0.30x 362.00x $53M -$707K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
